Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
Abstract Doxorubicin (DOX) is an anthracycline antibiotic frequently used against a wide range of cancers, including breast cancer. Although the drug is effective as a treatment against cancer, many patients develop heart failure (HF) months to years following their last treatment with DOX. The chal...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | Lipids in Health and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12944-022-01694-y |
| _version_ | 1811274809108070400 |
|---|---|
| author | Carmelita Abrahams Nicholas J. Woudberg Sandrine Lecour |
| author_facet | Carmelita Abrahams Nicholas J. Woudberg Sandrine Lecour |
| author_sort | Carmelita Abrahams |
| collection | DOAJ |
| description | Abstract Doxorubicin (DOX) is an anthracycline antibiotic frequently used against a wide range of cancers, including breast cancer. Although the drug is effective as a treatment against cancer, many patients develop heart failure (HF) months to years following their last treatment with DOX. The challenge in preventing DOX-induced cardiotoxicity is that symptoms present after damage has already occurred in the myocardium. Therefore, early biomarkers to assess DOX-induced cardiotoxicity are urgently needed. A better understanding of the mechanisms involved in the toxicity is important as this may facilitate the development of novel early biomarkers or therapeutic approaches. In this review, we discuss the role of high-density lipoprotein (HDL) particles and its components as possible key players in the early development of DOX-induced cardiotoxicity. HDL particles exist in different subclasses which vary in composition and biological functionality. Multiple cardiovascular risk factors are associated with a change in HDL subclasses, resulting in modifications of their composition and physiological functions. There is growing evidence in the literature suggesting that cancer affects HDL subclasses and that healthy HDL particles enriched with sphingosine-1-phosphate (S1P) and apolipoprotein A1 (ApoA1) protect against DOX-induced cardiotoxicity. Here, we therefore discuss associations and relationships between HDL, DOX and cancer and discuss whether assessing HDL subclass/composition/function may be considered as a possible early biomarker to detect DOX-induced cardiotoxicity. |
| first_indexed | 2024-04-12T23:25:53Z |
| format | Article |
| id | doaj.art-33bda5b623c74f33a027915287040279 |
| institution | Directory Open Access Journal |
| issn | 1476-511X |
| language | English |
| last_indexed | 2024-04-12T23:25:53Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj.art-33bda5b623c74f33a0279152870402792022-12-22T03:12:24ZengBMCLipids in Health and Disease1476-511X2022-09-0121111610.1186/s12944-022-01694-yAnthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?Carmelita Abrahams0Nicholas J. Woudberg1Sandrine Lecour2Cardioprotection Group, Cape Heart Institute and Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, Faculty of Health Sciences, University of Cape TownCardioprotection Group, Cape Heart Institute and Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, Faculty of Health Sciences, University of Cape TownCardioprotection Group, Cape Heart Institute and Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, Faculty of Health Sciences, University of Cape TownAbstract Doxorubicin (DOX) is an anthracycline antibiotic frequently used against a wide range of cancers, including breast cancer. Although the drug is effective as a treatment against cancer, many patients develop heart failure (HF) months to years following their last treatment with DOX. The challenge in preventing DOX-induced cardiotoxicity is that symptoms present after damage has already occurred in the myocardium. Therefore, early biomarkers to assess DOX-induced cardiotoxicity are urgently needed. A better understanding of the mechanisms involved in the toxicity is important as this may facilitate the development of novel early biomarkers or therapeutic approaches. In this review, we discuss the role of high-density lipoprotein (HDL) particles and its components as possible key players in the early development of DOX-induced cardiotoxicity. HDL particles exist in different subclasses which vary in composition and biological functionality. Multiple cardiovascular risk factors are associated with a change in HDL subclasses, resulting in modifications of their composition and physiological functions. There is growing evidence in the literature suggesting that cancer affects HDL subclasses and that healthy HDL particles enriched with sphingosine-1-phosphate (S1P) and apolipoprotein A1 (ApoA1) protect against DOX-induced cardiotoxicity. Here, we therefore discuss associations and relationships between HDL, DOX and cancer and discuss whether assessing HDL subclass/composition/function may be considered as a possible early biomarker to detect DOX-induced cardiotoxicity.https://doi.org/10.1186/s12944-022-01694-yCardio-oncologyAnthracyclineHigh-density lipoproteinsCardiac toxicity |
| spellingShingle | Carmelita Abrahams Nicholas J. Woudberg Sandrine Lecour Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage? Lipids in Health and Disease Cardio-oncology Anthracycline High-density lipoproteins Cardiac toxicity |
| title | Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage? |
| title_full | Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage? |
| title_fullStr | Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage? |
| title_full_unstemmed | Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage? |
| title_short | Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage? |
| title_sort | anthracycline induced cardiotoxicity targeting high density lipoproteins to limit the damage |
| topic | Cardio-oncology Anthracycline High-density lipoproteins Cardiac toxicity |
| url | https://doi.org/10.1186/s12944-022-01694-y |
| work_keys_str_mv | AT carmelitaabrahams anthracyclineinducedcardiotoxicitytargetinghighdensitylipoproteinstolimitthedamage AT nicholasjwoudberg anthracyclineinducedcardiotoxicitytargetinghighdensitylipoproteinstolimitthedamage AT sandrinelecour anthracyclineinducedcardiotoxicitytargetinghighdensitylipoproteinstolimitthedamage |